149 related articles for article (PubMed ID: 10435852)
1. Longitudinal study of soluble intercellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves' disease.
Sonnet E; Massart C; Gibassier J; Allannic H; Maugendre D
J Endocrinol Invest; 1999 Jun; 22(6):430-5. PubMed ID: 10435852
[TBL] [Abstract][Full Text] [Related]
2. Intercellular adhesion molecule-1 (ICAM-1) in the sera of patients with Graves' disease: correlation with disease activity and treatment status.
Fukazawa H; Yoshida K; Kaise N; Kiso Y; Sayama N; Mori K; Kikuchi K; Aizawa Y; Rikimaru A; Abe K
Thyroid; 1995 Oct; 5(5):373-7. PubMed ID: 8563475
[TBL] [Abstract][Full Text] [Related]
3. Clinical validity of intercellular adhesion molecule-1 (ICAM-1) and TSH receptor antibodies in sera from patients with Graves' disease.
Massart C; Sonnet E; Gibassier J; Maugendre D; Genetet B
Clin Chim Acta; 1997 Sep; 265(2):157-68. PubMed ID: 9385458
[TBL] [Abstract][Full Text] [Related]
4. Soluble intercellular adhesion molecule-1 (sICAM-1) in Graves' disease.
Balázs C; Kiss E
Acta Microbiol Immunol Hung; 1994; 41(4):451-6. PubMed ID: 7866729
[TBL] [Abstract][Full Text] [Related]
5. Behavior of soluble intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma.
De Bellis A; Bizzarro A; Gattoni A; Romano C; Di Martino S; Sinisi AA; Abbadessa S; Bellastella A
J Clin Endocrinol Metab; 1995 Jul; 80(7):2118-21. PubMed ID: 7541801
[TBL] [Abstract][Full Text] [Related]
6. Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy.
De Bellis A; Di Martino S; Fiordelisi F; Muccitelli VI; Sinisi AA; Abbate GF; Gargano D; Bellastella A; Bizzarro A
J Clin Endocrinol Metab; 1998 Apr; 83(4):1222-5. PubMed ID: 9543145
[TBL] [Abstract][Full Text] [Related]
7. Soluble intercellular adhesion molecule-1 (sICAM-1) in sera of patients with Graves' ophthalmopathy and thyroid diseases.
Heufelder AE; Bahn RS
Clin Exp Immunol; 1993 May; 92(2):296-302. PubMed ID: 8097976
[TBL] [Abstract][Full Text] [Related]
8. [Soluble forms of adhesion molecules sELAM-1 and sICAM-1 in Graves disease and toxic nodular goiter].
Modelska-Ziółkiewicz A; Gembicki M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):463-8. PubMed ID: 14768174
[TBL] [Abstract][Full Text] [Related]
9. Circulating selectins, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in hyperthyroidism.
Wenisch C; Myskiw D; Gessl A; Graninger W
J Clin Endocrinol Metab; 1995 Jul; 80(7):2122-6. PubMed ID: 7541802
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic role of adhesion molecules sELAM-1 and sICAM-1 in glucocorticoid therapy of active ophthalmopathy].
Modelska-Ziółkiewicz A; Gembicki M; Bednarek J; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):469-75. PubMed ID: 14768175
[TBL] [Abstract][Full Text] [Related]
11. Smoking and disease severity are independent determinants of serum adhesion molecule levels in Graves' ophthalmopathy.
Wakelkamp IM; Gerding MN; van der Meer JW; Prummel MF; Wiersinga WM
Clin Exp Immunol; 2002 Feb; 127(2):316-20. PubMed ID: 11876756
[TBL] [Abstract][Full Text] [Related]
12. Circulating intercellular adhesion molecule-1(ICAM-1) in sera of patients with Graves' disease and Hashimoto disease.
Lee JH; An MA; Jeon JS; Song CU; Shong M; Kim YK; Ro HK
Korean J Intern Med; 1995 Jan; 10(1):10-5. PubMed ID: 7626551
[TBL] [Abstract][Full Text] [Related]
13. Soluble endothelium-associated adhesion molecules in patients with Graves' disease.
Wenisch C; Myskiw D; Parschalk B; Hartmann T; Dam K; Graninger W
Clin Exp Immunol; 1994 Nov; 98(2):240-4. PubMed ID: 7525128
[TBL] [Abstract][Full Text] [Related]
14. [Usefulness of soluble ICAM-1 measurements for the evaluation of the disease activity and efficiency of therapy in patients with infiltrative Graves' ophthalmopathy].
Kulig G; Pilarska K; Kulig J; Krzyzanowska-Swiniarska B; Robaczyk M; Baraniak A
Pol Arch Med Wewn; 2002 Dec; 108(6):1161-9. PubMed ID: 12687928
[TBL] [Abstract][Full Text] [Related]
15. Soluble intercellular adhesion molecule-1 concentrations in patients with subacute thyroiditis and in patients with Graves' disease with or without ophthalmopathy.
Ozata M; Bolu E; Sengül A; Altinsoy HI; Turan M; Corakci A; Hacibektasoglu A; Gundogan MA
Endocr J; 1996 Oct; 43(5):517-25. PubMed ID: 8980891
[TBL] [Abstract][Full Text] [Related]
16. Effects of octreotide treatment on Graves' ophthalmopathy and circulating sICAM-1 levels.
Ozata M; Bolu E; Sengul A; Tasar M; Beyhan Z; Corakci A; Gundogan MA
Thyroid; 1996 Aug; 6(4):283-8. PubMed ID: 8875747
[TBL] [Abstract][Full Text] [Related]
17. [Serum levels of adhesion molecules (sICAM-1, sVCAM-1 and sP-selectin) in children and adolescents with thyroid diseases].
Bossowski A; Urban M; Citko A; Sobotko J; Bossowska A
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2000; 6(2):79-92. PubMed ID: 12818068
[TBL] [Abstract][Full Text] [Related]
18. A preliminary clinical application of sICAM-1 RIA in three kinds of thyroid disease.
Lu M; Fang P; Zhang Z; He H; Gao S; Hou B; Zheng R; Xiao Q; Yang L
Chin Med J (Engl); 2002 Oct; 115(10):1552-5. PubMed ID: 12490109
[TBL] [Abstract][Full Text] [Related]
19. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
[TBL] [Abstract][Full Text] [Related]
20. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
